-The Hindu Although urban Indians are slowly showing more openness in their attitudes towards women's attire, this is not the case when it comes to the issue of son preference As one of the world's most socially heterogeneous societies, building solidarity across social groups has been a singular challenge in India. Social bias in India is pervasive across a range of key cleavages - whether caste or class, region or religion. In this...

-The Telegraph New Delhi: A public health expert has questioned the Indian government's commitment to effectively tackling tuberculosis, citing slashed funds, late diagnoses and a failure to curb incorrect or inappropriate prescriptions by many private practitioners. India's plans to eliminate TB as a public health problem by 2050 will remain unachievable without sustained financial support, strong political will and stringent regulation, Mahavir Golechha has said. Golechha is a faculty member with the health...

-The Hindustan Times Around this time every year, news about the Annual Status of Education Report (ASER) survey creates a short-lived stir in the media over the dismal performance of children studying in State-run elementary schools. Pratham - the NGO which produces the ASER reports - carries out this nationwide evaluation of children's competence in reading and arithmetic, and presents the results of children's grade-wise scores. The sample consists of nearly...

-Tehelka Why is India struggling to feed its girls and women, who are in desperate need of nutrition, asks Ruhi Kandhari One out of three women or adolescent girls who come through that door are anaemic," says Dr Savita Agarwal, who runs a charitable clinic at a slum in north Delhi, pointing at the door of her clinic. "They cannot afford to eat meat, eggs, fruits and vegetables that provide iron." Fifty percent...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...